Nausea Associated With Chemo

Quarterly sales (approved)

Exp Date

March 05, 2021 (Est)

Amp Volatility Score


Catalyst Info & Data Links




  • Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors. Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced emesis 

  • Source - FDA Label (section 12.1)


Neurokinin-1 (NK-1) receptor antagonist:


  • ~4 million people per year receiving chemotherapy

  • ~CINV affects 70-80% of patients undergoing chemotherapy

  • See details

Updated by HC

HRTX, Civanti, Heron, CINV, Chemotherapy-induced nausea and vomiting

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See What The Community Is Saying - Click To See Full Post

HRTX - Heron Therapeutics Resu...

#HRTX "announced that the New Drug Application (NDA) was resubmitted to the U.S. Food and Drug Administration (FDA) for #HTX011, an investigational agent for the management of postoperative pain. Th...

HRTX - Announces Successful Ou...

#HRTX announced a successful Type A meeting with the U.S. Food and Drug Administration (FDA) in which alignment was reached on the plans for the Company to resubmit the New Drug Application (NDA) for ...

HRTX - Heron Therapeutics Anno...

#HRTX "announced financial results for the three and nine months ended September 30, 2020 and highlighted recent corporate updates.
Recent Corporate Updates
Pain Management Franchise European Commiss...

VNDA - Interim Analysis from #...

#VNDA's interim analysis of the #ODYSSEY study demonstrated that hospitalized patients with #COVID-19 pneumonia improved sooner when treated with #tradipitant as compared to placebo. Summary of find...

HRTX - Heron Therapeutics Rece...

#HRTX "announced that the European Commission has granted a marketing authorization for ZYNRELEF (formerly known as HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized...

Trilaciclib NDA Filing (GTHX)...

We are fans of GTHX and hope things go well. But we are worried if NDA for Trilaciclib in NSCLC is accepted and accelerated date is set, that expedited PDUFA is too rushed for FDA during a pandemic. S...

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon